ANTIBODY MODIFICATION METHOD FOR PURIFYING BISPECIFIC ANTIBODY - European Patent Office - EP 2009101 A1

Antenna system, in particular for use in a mobile phone handset, and corresponding control method - European Patent Office - EP 1091447 A1

Phospholipase for treatment of immunosuppression - European Patent Office - EP 2960252 A1

A Comparative Investigation of the Bispecific Antibody: Expression in Expi293F Cells and E.Coli

Aims: Bispecific antibodies are capable of targeting two cell surface markers simultaneously. Blinatumomab an anti-CD3/CD19 Bispecific T cell engager antibody (BiTE) is approved for clinical application by FDA. This BiTE effectively targets malignant cells in ALL (Acute Lymphoblastic Leukemia) patients. For production of large quantities of such antibodies in industrial settings choice of host ...

Woodchuck Hepatitis Virus Post-Transcriptional Regulation Element (WPRE) Promotes Anti-CD19 BiTE Expression in Expi293 Cells

Background: Bispecific antibodies represent an important class of mAbs, with great therapeutic potentials due to their ability to target simultaneously two distinct epitopes. The generation of functional bispecific antibodies with the highest possible yields is particularly critical for the production of these compounds on industrial scales. Anti- CD3 × CD19 bsAb is a bispecific T-cell engager ...

Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody

Created using the Company’s patented DOCK-AND-LOCK protein conjugation technology, (E1)-3s is a bispecific antibody that targets the TROP-2 receptor expressed by many solid cancers and the CD3 antigen present on T cells. The redirecting bispecific antibody was developed for the potential treatment of gastric and pancreatic cancers, since these and various other solid cancers express high-levels...